Elite in Ciliary Dyskinesia-Bronchiectasis

Felix C. Ringshausen

Carl Neuberg Str 1, 
Hannover, NI, DE 
Elite in Ciliary Dyskinesia-Bronchiectasis
Carl Neuberg Str 1, 
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Felix Ringshausen practices in Hannover, Germany. Mr. Ringshausen is rated as an Elite expert by MediFind in the treatment of Ciliary Dyskinesia-Bronchiectasis. His top areas of expertise are Bronchiectasis, Ciliary Dyskinesia-Bronchiectasis, Allergic Bronchopulmonary Aspergillosis, Cystic Fibrosis, and Lung Transplant.

His clinical research consists of co-authoring 130 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles in the study of Ciliary Dyskinesia-Bronchiectasis.

Gender
Male

Locations

Carl Neuberg Str 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis
Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2024
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Enrollment Status: Completed
Publish Date: January 18, 2023
Intervention Type: Drug, Other
Study Drug: Lenabasum
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

130 Total Publications

Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study.
Upper Airway Microbiome, Mucociliary Function, and Clinical Outcomes in Bronchiectasis: Data from the EMBARC-BRIDGE Study.
Journal: American journal of respiratory and critical care medicine
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ringshausen's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile